ACTION-MS online: an online tailored depression intervention for people with multiple sclerosis
The current randomised controlled trial will examine whether the 8-week internet-based ACTION-MS online depression intervention is feasible, acceptable and effective in the treatment of mild to moderate levels of depressive symptoms in people with MS. We will also be looking at the cost-effectiveness of providing this online intervention as part of routine care for people with […]
Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasticity
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
PLATYPUS – the Australian extension of the OCTOPUS trial
PLATYPUS is the Australian extension of a revolutionary trial based in the United Kingdom (UK) called OCTOPUS, which aims to enroll participants in the UK and Australia over the next few years. OCTOPUS (including PLATYPUS) is a trial which will test multiple treatments with the aim to find one that can slow down, and ultimately […]
Fatigue In Relapsing Multiple Sclerosis – Epstein Barr Virus (FIRMS-EBV) Treatment Trial
Fatigue is a common symptom for many people with MS and it does not respond to traditional MS treatments. It has been suggested that fatigue in MS could relate to chronic infection with the Epstein Barr Virus (EBV). In this clinical trial, two drug therapies with antiviral effects against EBV will be tested for their […]
Phase III, multicentre, randomised, double-blinded, placebo-controlled, MAMS trial of SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression (STOP-MS)
Multiple sclerosis (MS) is a potentially devastating disease of the central nervous system and progressive MS, which occurs in up to two-thirds is the most severe form. Current therapies for MS have limited effect in the progressive stage. Recent studies have confirmed that the primary cause of MS is latent infection with Epstein-Barr virus (EBV). […]